Pasithea Therapeutics Corp.: AMERIPRISE FINANCIAL INC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Ameriprise Financial Inc. filed an amended Schedule 13G with the SEC (accession 0001193125-26-462606) updating its beneficial ownership stake in Pasithea Therapeutics Corp. The filing, submitted under CIK 0001193125, is a routine passive-investor disclosure rather than an activist position. The amendment signals a change in Ameriprise's reported holdings in the clinical-stage biotech, though the filing summary did not specify the revised share count or percentage. Investors should watch for the full 13G exhibit to confirm whether Ameriprise increased, trimmed or maintained its position, and whether the change crosses the 5% reporting threshold that would sharpen scrutiny of the holder base.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Ameriprise Financial Inc., Pasithea Therapeutics Corp.